Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages 3330-3336

  Moran, Teresa ^a,b   Sequist, Lecia V ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOKERATIN 7; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DYSPNEA; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; NEEDLE BIOPSY; NEUTROPENIA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN DISEASE; THORAX RADIOGRAPHY;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84866601770     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.1858     Document Type: Article

References (65)

1. Patel JD, Hensing TA, Rademaker A, et al: Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27:3284-3289, 2009
2. Ettinger DS, Akerley W, Bepler G, et al: Non-small cell lung cancer. J Natl Compr Canc Netw 8:740-801, 2010
3. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137, 2001
4. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
5. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
6. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004 (Pubitemid 39209661)
7. Sequist LV, Bell DW, Lynch TJ, et al: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587-595, 2007 (Pubitemid 350002967)
8. Pham D, Kris MG, Riely GJ, et al: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24:1700-1704, 2006 (Pubitemid 46622141)
9. D'Angelo SP, Pietanza MC, Johnson ML, et al: Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 29:2066-2070, 2011
10. Greulich H, Chen TH, Feng W, et al: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2:e313, 2005
11. Sharma SV, Bell DW, Settleman J, et al: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181, 2007
12. Sequist LV, Martins RG, Spigel D, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442-2449, 2008
13. Inoue A, Suzuki T, Fukuhara T, et al: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24:3340-3346, 2006 (Pubitemid 46638887)
14. Asahina H, Yamazaki K, Kinoshita I, et al: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95: 998-1004, 2006 (Pubitemid 44606825)
15. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
16. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
17. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
18. Zhou C, Wu Y-L, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicenter, open-label, randomized, phase 3 study. Lancet Oncol 12:735-742, 2011
19. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
20. Jackman DM, Yeap BY, Sequist LV, et al: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12:3908-3914, 2006 (Pubitemid 44078074)
21. Taron M, Ichinose Y, Rosell R, et al: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11:5878-5885, 2005 (Pubitemid 41170316)
22. Cortes-Funes H, Gomez C, Rosell R, et al: Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16:1081-1086, 2005 (Pubitemid 41418309)
23. Han SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501, 2005
24. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2009
25. Sequist LV, Heist RS, Shaw AT, et al: Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 22:2616-2624, 2011
26. Pirker R, Herth FJ, Kerr KM, et al: Consensus for EGFR mutation testing in non-small cell lung cancer: Results from a European workshop. J Thorac Oncol 5:1706-1713, 2010
27. Garcia-Olivé I, Sanz-Santos J, Andreo F, et al: Detection of epidermal growth factor receptor mutations in samples obtained with endobronchial ultrasound-guided transbronchial needle aspiration: A short review. Ann Resp Med 1:85-88, 2010
28. Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al: A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 3:1224-1235, 2008
29. Navani N, Brown JM, Nankivel M, et al: Suitability of EBUS-TBNA specimens for subtyping and genotyping of NSCLC: A multi-centre study of 774 patients. Am J Respir Crit Care Med [epub ahead of print on April 13, 2011]
30. Billah S, Stewart J, Staerkel G, et al: EGFR and KRAS mutations in lung carcinoma: Molecular testing by using cytology specimens. Cancer Cytopathol 119:111-117, 2011
31. Solomon SB, Zakowski MF, Pao W, et al: Core needle lung biopsy specimens: Adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol 194:266-269, 2010
32. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285, 2011
33. Azzoli CG, Temin S, Aliff T, et al: 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29:3825-3831, 2011 [Erratum: J Clin Oncol 29:4725, 2011]
34. Keedy VL, Temin S, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121-2127, 2011
35. D'Addario G, Früh M, Reck M, et al: Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v116-v119, 2010
36. Gridelli C, Besse B, Marinis F, et al: The Lugano consensus on advanced NSCLC: ESMO recommendation 2011 - Advanced disease. Lung Cancer 71:S3, 2011 (suppl 2)
37. Thongprasert S, Duffield E, Saijo N, et al: Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 6:1872-1880, 2011
38. Fukuoka M, Wu YL, Thongprasert S, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866-2874, 2011
39. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374:1432-1440, 2009
40. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
41. Pao W, Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760-774, 2010
42. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26, 2011
43. Oxnard GR, Arcila ME, Chmielecki J, et al: New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 17:5530-5537, 2011
44. Chaft JE, Oxnard GR, Sima CS, et al: Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design. Clin Cancer Res 17:6298-6303, 2011
45. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22:777-784, 2004 (Pubitemid 41103588)
46. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 22:785-794, 2004 (Pubitemid 41103589)
47. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
48. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552, 2007 (Pubitemid 46733081)
49. Jänne PA, Wang X, Socinski MA, et al: Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol [epub ahead of print on April 30, 2012]
50. Miller VA, Das A, Rossi M, et al: A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol 27:407s, 2009 (suppl 18; abstr LBA8002)
51. Sequist LV, Besse B, Lynch TJ, et al: Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3076-3083, 2010
52. Miller VA, Hirsh V, Cadranel J, et al: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol 13:528-538, 2012
53. Yang CH, Shih JY, Su WC, et al: Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial. Lancet Oncol 13:539-548, 2012
54. Janjigian YY, Groen HJ, Horn L, et al: Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 29:482s, 2011 (suppl 15; abstr 7525)
55. Janne PA, Reckamp K, Koczywas M, et al: Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. J Clin Oncol 27:422s, 2009 (suppl 15; abstr 8063)
56. Park K, Heo DS, Cho BC, et al: PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study. J Clin Oncol 28:562s, 2010 (suppl 15; abstr 7599)
57. Ramalingam SS, Blackhall F, Krzakowski M, et al: Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 30:3337-3344, 2012
58. Mok T, Spigel DR, Park MA, et al: Efficacy and safety of PF-0029804 (PF299), an oral, irreversible, pan-human epidermal growth receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). J Cin Oncol 28:547s, 2010 (suppl 15; abstr 7537)
59. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010 [Erratum: N Engl J Med 364:588, 2011]
60. Bergethon K, Shaw AT, Ignatius Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012
61. Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 12:1004-1012, 2011
62. Ou SH, Kwak EL, Siwak-Tapp C, et al: Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6:942-946, 2011
63. De Grève J, Teugels E, Geers C, et al: Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 76:123-127, 2012
64. Kohno T, Ichikawa H, Totoki Y, et al: KI5FB-RET fusions in lung adenocarcinoma. Nat Med 18:375-377, 2012
65. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005